Oncotarget Sponsoring Researchers and Making Changes to their Journal

Oncotarget, an online biomedical journal has been rising stronger in its line of work and expanding upon its efforts to deliver more information to its reader base. The Oncotarget journal will be partnering up with a handful of trusted archives and indexes to provide only the most accurate numbers, statistics, and other pieces of information.

 

The online biomedical journal publishes research in a number of disciplines such as Immunology, Chromosomes, pathology, and many others. The Oncotarget journal has two editors in chief whose names are well-known in the fields of oncology and anti-aging. From the Rowell Park Cancer Institute, based in New York City, Dr. Andrei V. Gudkov has been a par of the editing team since the journal was conceived. Dr. Andrei V. Gudkov has been working in oncology for many decades, and he also specializes in cardiology. Dr. Mikhail Blogoskolnny, Russian scientists, has been doing oncology research for decades in the United States of America. He used to work at the same Roswell Park Cancer Institute but moved on from it in 2016. Learn more about Oncotarget at researchgate.net

Oncotarget is strongly focused on promoting communication and the exchange of ideas among scientists and medical professionals from around the world. Oncotarget awarded four biomedical researchers with the opportunity to attend the conference on Frontiers in Cancer Science 2017. The meeting took place in Singapore, and it was filled with thousands of medical professional and medical scientists.

Visit: https://oncotarget.msubmit.net/cgi-bin/main.plex

 

The four researchers that received grants to got to the Frontier for Cancer Science 2017 were from the Aligarh Muslim University, the National Institute of Immunology in India, and from the Universty of Torino in Italy. Each of them contributed to the conversation at the large conference. The event lasted a full three days from Nov. 6 to Nov. 8. The supported attendees presented their work in research on topics such as chemoresistance, malignant pleural mesothelioma, Cyclin F, as well as several other topics of discussion.

 

The Frontier for Cancer Science 2017 was hosted by a number of prominent organizations. Those included the local Genome Institute of Singapore, theInstitute of Molecular and Cell Biology, the Leek Kong Chian School of Medicine and others. Check the journal at SCImago Journal & Country Rank.

Dr. Clay Siegall: In Pursuit of Greatness

There are many brilliant-minded individuals in this world and many of these people are working in cancer research. This is one of the most demanding industries on earth, but is has also saved hundreds of thousands of lives on a worldwide-scale. The industry has been buzzing with activity as of late because of all the new discoveries. Some discoveries are good while others aren’t so good. Lets dig a bit deeper on this topic of discussion. Revolutionary-science is changing the game when it comes to fighting cancer. Some of the most technologically advanced medications are on the market right now, and they are saving lives at a dramatic rate. Antibody-based conjugates have helped to revolutionize the industry thanks to their wonderful lifesaving benefits.

Seattle Genetics, a Washington-based oncology company, is at the forefront of it all. Dr. Clay Siegall co-founded this organization back in 1998, and it has produced some amazing cancer-fighting medications. The company’s flagship drug, ADCETRIS, is now being used in 66 countries worldwide. This cancer therapy is aggressive at attacking cancer cells within the body, but it by-passes all of the good cells. This drastically cuts-back on sickening side effects, which is a bonus for all patients. Dr. Siegall has implemented his strong principles of drug development, scientific innovation and rigorous research into each and every medication. In other words, the mortality rate is much lower with (ADCs) on the scene. On the other hand, there are other specific types of cancer that these medications can’t fight. The National Cancer Institute reported that a shocking 40 percent of men and women will be diagnosed with cancer in their lifetime.

Hodgkin’s Lymphoma affects young people more so than other older people. Studies show that 8,000 new cases are present each year among this group. The problem is that most people don’t have access to the medications. Research and drugs are what’s keeping the industry afloat. If cancer gets tougher, then cancer research will get tougher and Dr. Clay Siegall has a firm understanding of this. This is the new wave of cancer-breakthrough therapies and the future is still looking very promising.